SCHEMBL29762960

SCHEMBL29762960

Cn1c(N)c2ncn([C@@H]3O[C@H](CO)[C@@H](O)[C@H]3O)c2nc1=O

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP2C19 P33261 1/20 0.62
▸ LMNA P02545 2/20 0.61
▸ NT5E P21589 1/20 0.61
▸ HIF1A Q16665 1/20 0.61
▸ GMNN O75496 1/20 0.61
▸ ALDH1A1 P00352 1/20 0.61
▸ TP53 P04637 1/20 0.61
▸ NFKB1 P19838 1/20 0.61
▸ DNMT1 P26358 1/20 0.61
▸ THPO P40225 1/20 0.61
▸ MTOR P42345 1/20 0.61
▸ HTT P42858 1/20 0.61
▸ RAB9A P51151 1/20 0.61
▸ BLM P54132 1/20 0.61
▸ HBB P68871 1/20 0.61
▸ PMP22 Q01453 1/20 0.61
▸ ADORA2A P29274 5/20 0.61
▸ ADORA3 P0DMS8 3/20 0.61
▸ ADORA2B P29275 3/20 0.61
▸ ADORA1 P30542 2/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14614880 1.00 CYP2C19 (0.62) CYP2C19LMNANT5EHIF1AGMNN
SCHEMBL31685319 0.89 ADORA2A (0.53) CYP2C19ADORA2AADORA3ADORA2BADORA1
SCHEMBL31685809 0.86 ADORA3 (0.62) CYP2C19LMNANT5EHIF1ATP53
SCHEMBL31685223 0.85 ADORA1 (0.58) ADORA2AADORA3ADORA2BADORA1
SCHEMBL31685494 0.85 HPGD (0.57) CYP2C19LMNANT5EHIF1AGMNN
SCHEMBL31685571 0.85 CA5A (0.67) NT5EADORA1
SCHEMBL62505 0.84 CYP2C19 (0.62) CYP2C19LMNANT5EHIF1AADORA2A
SCHEMBL343478 0.84 CYP2C19 (0.62) CYP2C19LMNANT5EHIF1AADORA2A
SCHEMBL14931005 0.84 CYP2C19 (0.62) CYP2C19LMNANT5EHIF1AADORA2A
SCHEMBL18512921 0.84 CYP2C19 (0.62) CYP2C19LMNANT5EHIF1AADORA2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4734923-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS L'OREAL (FR) 2026-05-06 — — EP disclosed
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE TEAM MEDICAL, LLC 2025-09-18 — — US disclosed
WO-2025096719-A1 BIOACTIVE WALNUT PEPTIDES AND COMPOSITIONS FOR TOPICAL TREATMENT OF SKIN L'OREAL (FR) 2025-05-08 — — WO disclosed
WO-2025006412-A1 CLEANSING COMPOSITIONS COMPRISING DIVALENT SALTS L'OREAL (FR) 2025-01-02 — — WO disclosed
EP-4444253-A1 COMPOSITION COMPRISING A COMBINATION OF POLYGLYCEROL ESTERS AND A FILLER L'OREAL (FR) 2024-10-16 — — EP disclosed
EP-4440531-A1 KIT AND METHOD FOR TREATING SKIN L'OREAL (FR) 2024-10-09 — — EP disclosed
EP-4422760-A1 COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF RETINOL L'OREAL (FR) 2024-09-04 — — EP disclosed
EP-4422579-A1 COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL L'OREAL (FR) 2024-09-04 — — EP disclosed
WO-2024144987-A1 SKIN PERFECTING AND TIGHTENING COMPOSITIONS L'OREAL (FR) 2024-07-04 — — WO disclosed
WO-2024126604-A1 PROCESS FOR PREPARING A COSMETIC ARTICLE AND COSMETIC ARTICLE THAT IS ADAPTABLE TO THE SHAPE OF THE FACE, NECK AND/OR NECKLINE AND CHARGED WITH HYDROPHILIC ACTIVE AGENT L'OREAL (FR) 2024-06-20 — — WO disclosed
EP-4271358-A1 SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE L'OREAL (FR) 2023-11-08 — — EP disclosed
EP-4271352-A1 SKIN PERFECTING COMPOSITIONS AND METHODS OF USE L'OREAL (FR) 2023-11-08 — — EP disclosed
WO-2023126397-A1 KIT FOR CUSTOMIZING A COSMETIC COMPOSITION L'OREAL (FR) 2023-07-06 — — WO disclosed
WO-2023104924-A1 COMPOSITION COMPRISING A COMBINATION OF POLYGLYCEROL ESTERS AND A FILLER L'OREAL (FR) 2023-06-15 — — WO disclosed
WO-2023101902-A1 KIT AND METHOD FOR TREATING SKIN L'OREAL (FR) 2023-06-08 — — WO disclosed
WO-2023076543-A1 COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF RETINOL L'OREAL (FR) 2023-05-04 — — WO disclosed
WO-2023076458-A1 COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL L'OREAL (FR) 2023-05-04 — — WO disclosed
WO-2023076578-A1 COSMETIC COMPOSITIONS COMPRISING HIGH AMOUNTS OF HYDROXYPROPYL TETRAHYDROPYRANTRIOL L'OREAL (FR) 2023-05-04 — — WO disclosed
WO-2022146700-A1 SKIN PERFECTING COMPOSITIONS AND METHODS OF USE L'OREAL (FR) 2022-07-07 — — WO disclosed
WO-2022146701-A1 SKIN PERFECTING COSMETIC COMPOSITIONS AND METHODS OF USE L'OREAL (FR) 2022-07-07 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289840-A1 RNA STABILIZING SUBSTANCES AND METHODS OF USE SYNCRIP, SNRPA, RNASE1 CYP2C19 4442/4885LMNA 240/4885NT5E 202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback